PACB vs PEN Stock Comparison

PEN currently leads PACB in this stock comparison, with AIQ scores of 66 vs 48. The clearest difference is risk resilience, while PACB has the stronger momentum profile.

Market data as of Nov 18, 2026 market close· AIQ score gap 18 points
PACB
Healthcare
vs
PEN
Healthcare
PACB
Pacific Biosciences of California, Inc.
Price
$1.83
Day move
+0.55%
AIQ Score
48/100
Best edge
Momentum
Sector
Healthcare
PEN
Penumbra, Inc.
Leads
Price
$321
Day move
+0.47%
AIQ Score
66/100
Best edge
Risk Resilience
Sector
Healthcare

What is the main difference between PACB and PEN?

PEN leads the current stock comparison as Penumbra, Inc., with the clearest separation coming from risk resilience and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Pacific Biosciences of California, Inc. vs Penumbra, Inc.

Data as of Nov 18, 2026· market close· Healthcare· Coverage 61/66 fields· High confidence
AIQ VerdictStableAIQ Comparison Conviction 9/10

PEN leads

PEN leads by 18 AIQ points, primarily on Risk Resilience and Quality, but the lead has narrowed from 23 points over 30 sessions.

Stable: 4 of 5 evidence groups support PEN, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 4 of 5Comparison trend: Weakening
PACB

Pacific Biosciences of California, Inc.

AIQ Score
48/100
AIQ Edge Score
4/10
PEN

Penumbra, Inc.

Leads
AIQ Score
66/100
AIQ Edge Score
8/10

The Algovestiq AIQ Score currently favors PEN over PACB, 66 versus 48 as of Nov 18, 2026. PEN's advantage is driven primarily by stronger risk resilience and quality, while PACB holds the stronger momentum profile. PEN also shows the stronger technical structure relative to its 50-day moving average. 4 of 5 covered evidence groups favor PEN today, and the comparison is rated Stable on stability: the leader's advantage has been narrowing. PEN lead: Weakening — the AIQ differential moved from 23 to 18 points over 30 sessions.

Compare Pacific Biosciences of California, Inc. and Penumbra, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

PACB
-91.9%
PEN
+23.4%

Price return comparison

Growth of $10,000, price only

PACB $807 · PEN $12,344

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare PACB and PEN against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

PACB advantage
0
PEN advantage
  • Risk Resilience24 vs 92
    PEN +68
  • Quality32 vs 78
    PEN +46
  • Momentum84 vs 56
    PACB +28
  • Value23 vs 48
    PEN +25

4 of 5 evidence groups favor PEN. PEN’s edge is concentrated in risk resilience and quality; PACB keeps a meaningful momentum edge.

What changed since the last close

Latest scored session 2026-11-18, compared against the prior scored session 2026-11-17.

PACB0 AIQ

Largest factor move: Value -1, not enough on its own to move the overall score.

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.56x)
  • Stochastic Oversold Bounce — bullish, momentum, short horizon
PEN0 AIQ

Largest factor move: Momentum +2, not enough on its own to move the overall score.

New signals

  • Low Volume Rally Warning — bearish, volume, short horizon (0.60x)

PEN's lead was unchanged in the latest session.

Deeper signal detail for each name lives on its own signals page — PACB and PEN both carry a full feed there.

The central trade-off

PEN (Penumbra, Inc.): the stronger current systematic profile, led by risk resilience and quality.

PACB (Pacific Biosciences of California, Inc.): the counter-case, on momentum, technicals — but at materially higher volatility, 114.1% against 10.9%.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

PEN

PEN on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

PEN

PEN on combined revenue and EPS growth.

Value

PEN

PEN on the peer-relative Value factor, by 25 points.

Momentum

PACB

PACB on the Momentum factor, by 28 points.

Lower downside

PEN

PEN on Risk Resilience, by 68 points.

Analyst upside

Even

Analyst targets are level or not covered for both names.

AIQ vs Wall Street

Where the systematic read and the analyst consensus line up — and where they do not.

MeasurePACBPENNote
Implied upside to target+5.2%—Level
Target dispersion+59.7%—Lower is tighter analyst agreement
ConsensusHoldHoldContext, not a primary driver
Analysts covering817Higher coverage generally improves confidence

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

4 of 5 covered evidence groups favor PEN. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScorePEN48 vs 66
FundamentalsPENon balancerevenue growth 4% vs 5.2%; EPS growth 14.3% vs 21.6%; TTM ROE 61.7% vs 2.7%; gross margin 34.5% vs 68%; operating margin -99.6% vs 12.1% — PEN takes 4 of 5 decided legs, not all of them
ValuationPENValue 23 vs 48
TechnicalsPACBPrice vs 50-day -8.7% vs 0.1%; vs 200-day 22.4% vs -1.5%
Risk ResiliencePENRisk Resilience 24 vs 92
Analyst expectationsNot coveredNot covered

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of PACB and PEN and are excluded from the count.

AIQ Decision Stability

Stable

The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.

  • The AIQ gap is wide at 18 points. (supports the conclusion holding)
  • 4 of 5 covered evidence groups point the same way. (supports the conclusion holding)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on PEN.

How the comparison changed

120 daily snapshots · Jun 1 – Nov 18

PEN lead: Weakening — the AIQ differential moved from 23 to 18 points over 30 sessions.

Jun 1PACB leads above the line · PEN leads belowNov 18
Today
PEN +18
48 vs 66
7 sessions ago
PEN +17
49 vs 66
30 sessions ago
PEN +23
44 vs 67
90 sessions ago
PEN +31
30 vs 61

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

PACBConflicted

3 bullish / 3 bearish / 1 neutral, conflicted

Only PACB

  • Golden Cross Active — bullish, trend, long horizon (25.22%)
  • ATR Expansion - Breakout Mode — neutral, volatility, short horizon (14.16%)
  • Beta Spike Warning — bearish, risk_regime, long horizon
  • Stochastic Oversold Bounce — bullish, momentum, short horizon
PENConflicted

2 bullish / 3 bearish / 4 neutral, conflicted

Only PEN

  • Bollinger Band Squeeze — neutral, volatility, short horizon (2.5%)
  • Death Cross Active — bearish, trend, long horizon (1.74%)
  • ADX Trend Weakening — neutral, trend, medium horizon
  • ATR Contraction - Coiling — neutral, volatility, short horizon (0.79%)
  • Drawdown Recovery Signal — bullish, risk_regime, long horizon (-2.7%)
  • EMA Ribbon Compression — neutral, trend, medium horizon

Both carry 3 more signals that do not separate them: EMA Ribbon Expansion Bullish, Low Volume Rally Warning, MACD Histogram Expanding Bearish.

PEN leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

PACBNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.55%, AIQ 0 points).

PENNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.47%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1PACB closes the Risk Resilience gap — currently 68 points behind, the largest single contributor to PEN's edge.
  2. 2PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
  3. 3PEN's conflicting signal state resolves bearish — it currently carries 2 bullish and 3 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 5 points over 30 sessions, and a further 18-point move would eliminate PEN's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

PEN leads on balance
MetricPACBPEN
Revenue growth (YoY)4%5.2%
EPS growth (YoY)14.3%21.6%
Gross margin34.5%68%
Operating margin-99.6%12.1%
Return on equity (TTM)61.7%2.7%
Debt to equity-11.490.13

Performance

PACB leads 4 of 6 windows
MetricPACBPEN
1 week (5 sessions)-13.1%0.5%
1 month (20 sessions)13.3%0%
3 months (63 sessions)62%-1.9%
6 months (126 sessions)75%-0.4%
Year to date4.8%3.2%
1 year (252 sessions)12.6%14.5%

Technicals

PACB has the stronger structure
MetricPACBPEN
RSI (14)43.149.5
ADX (14)27.417
Price vs 50-day-8.7%0.1%
Price vs 200-day22.4%-1.5%
Volatility (1M, annualized)114.1%10.9%

Risk

PEN is the more resilient
MetricPACBPEN
Beta2.10.19
Sharpe ratio0.610.62
Sortino ratio0.961.15
Max drawdown-58.4%-12.2%
Current drawdown-32.4%-10.7%
Annualized volatility93.5%19.5%
Value at risk (95%)-9%-0.9%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, PACB or PEN?

On the Algovestiq AIQ Score, PEN is the stronger of the two as of Nov 18, 2026, scoring 66 against PACB's 48. The edge comes from risk resilience and quality. PACB is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is PACB or PEN the better buy right now?

PEN carries the stronger systematic profile as of Nov 18, 2026, and the comparison is rated Stable — 4 of 5 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.

Why does the AIQ Score favor PEN over PACB?

The composite weights Quality, Value, Momentum and Risk Resilience. PEN leads Risk Resilience by 68 points; PEN leads Quality by 46 points; PACB leads Momentum by 28 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, PACB or PEN?

Analyst price targets imply +5.2% upside for PACB and not covered for PEN. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, PACB or PEN?

PEN is the better-valued of the two on the peer-relative Value factor. PEN on the peer-relative Value factor, by 25 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, PACB or PEN?

PEN on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, PACB or PEN?

PACB on the Momentum factor, by 28 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, PACB or PEN?

PEN is the more resilient of the two, so the other name carries the higher downside risk. PEN on Risk Resilience, by 68 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is PACB more profitable than PEN?

The profitability evidence is mixed: gross margin 34.5% vs 68%; operating margin -99.6% vs 12.1%; ttm roe 61.7% vs 2.7%. PACB leads on one measure and PEN on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is PEN's lead over PACB getting stronger or weaker?

PEN lead: Weakening — the AIQ differential moved from 23 to 18 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-01 and 2026-11-18. The lead has not changed hands in that window.

What would change the PACB vs PEN verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: PACB closes the Risk Resilience gap — currently 68 points behind, the largest single contributor to PEN's edge; PACB's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; PEN's conflicting signal state resolves bearish — it currently carries 2 bullish and 3 bearish rules at once; the narrowing continues — the lead has already given back 5 points over 30 sessions, and a further 18-point move would eliminate PEN's advantage entirely.

What do the current signals say about PACB and PEN?

PACB: 3 bullish / 3 bearish / 1 neutral, conflicted. PEN: 2 bullish / 3 bearish / 4 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on PACB is Golden Cross Active (bullish, long horizon). On PEN it is Death Cross Active (bearish, long horizon).

Compare PACB and PEN with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.